Turnstone Biologics Past Earnings Performance
Past criteria checks 0/6
Turnstone Biologics's earnings have been declining at an average annual rate of -78.1%, while the Biotechs industry saw earnings growing at 11.7% annually. Revenues have been declining at an average rate of 73.7% per year.
Key information
-78.1%
Earnings growth rate
61.7%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -73.7% |
| Return on equity | -55.9% |
| Net Margin | -286.1% |
| Last Earnings Update | 31 Dec 2023 |
Revenue & Expenses BreakdownBeta
How Turnstone Biologics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 19 | -55 | 18 | 58 |
| 30 Sep 23 | 30 | -52 | 18 | 0 |
| 30 Jun 23 | 40 | -51 | 18 | 0 |
| 31 Mar 23 | 82 | -18 | 18 | 0 |
| 31 Dec 22 | 73 | -31 | 18 | 78 |
| 31 Dec 21 | 101 | 3 | 14 | 0 |
Quality Earnings: TSBX is currently unprofitable.
Growing Profit Margin: TSBX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if TSBX's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare TSBX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TSBX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-10.9%).
Return on Equity
High ROE: TSBX has a negative Return on Equity (-55.95%), as it is currently unprofitable.